Immunic, Inc. (IMUX): Price and Financial Metrics


Immunic, Inc. (IMUX): $2.24

0.17 (+8.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMUX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IMUX Stock Price Chart Interactive Chart >

Price chart for IMUX

IMUX Price/Volume Stats

Current price $2.24 52-week high $14.50
Prev. close $2.07 52-week low $1.11
Day low $2.06 Volume 1,869,776
Day high $2.30 Avg. volume 1,104,017
50-day MA $1.42 Dividend yield N/A
200-day MA $3.92 Market Cap 99.36M

Immunic, Inc. (IMUX) Company Bio


Immunic Inc. (formerly Vital Therapies) is a biotherapeutic company developing a cell-based therapy targeting the treatment of liver failure. The company was founded in 2003 and is based in San Diego, California.


IMUX Latest News Stream


Event/Time News Detail
Loading, please wait...

IMUX Latest Social Stream


Loading social stream, please wait...

View Full IMUX Social Stream

Latest IMUX News From Around the Web

Below are the latest news stories about IMMUNIC INC that investors may wish to consider to help them evaluate IMUX as an investment opportunity.

Immunic to Participate in Scientific and Investor Conferences in February

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in February:

Yahoo | January 25, 2023

Quite a few insiders invested in Immunic, Inc. (NASDAQ:IMUX) last year which is positive news for shareholders

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Yahoo | January 18, 2023

Immunic: Revisiting A 'Lottery Ticket'

"I guess I think of lotteries as a tax on the mathematically challenged." - Roger Jones

When we last looked in on a small-cap biotech company called Immunic, Inc. (IMUX), the country was coming off the first series of Covid-related lockdowns. We concluded that article around Immunic by calling it a 'lottery ticket' that was only worthy of ...

Busted IPO Forum on Seeking Alpha | December 28, 2022

Immunic (IMUX) Receives a Buy from Wedbush

E ratio of -0.48.

Brian Anderson on TipRanks | November 21, 2022

Immunic Soars on Promising Multiple Sclerosis Data

Shares of clinical-stage biopharmaceutical company Immunic (NASDAQ:IMUX) are soaring higher today after the company announced promising data from a Phase 2 study evaluating vidofludimus calcium (IMU-838) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Long-term treatment with Immunic’s lead candidate was associated with a low rate of disability worsening over time. Further, the results compare favorably with available trial data for current MS medications. Despite today’s price gains, Immunic shares are still down ~87% year-to-date. Moreover, short interest in the stock remains elevated at about 23.6% at present.

Kailas Salunkhe on TipRanks | November 17, 2022

Read More 'IMUX' Stories Here

IMUX Price Returns

1-mo 76.38%
3-mo 26.55%
6-mo -36.72%
1-year -79.58%
3-year -74.16%
5-year -99.09%
YTD 60.00%
2022 -85.37%
2021 -37.41%
2020 57.63%
2019 27.63%
2018 -96.81%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6765 seconds.